⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NKTR News
Nektar Therapeutics
Pomerantz LLP Announces Class Action Filing Against Nektar Therapeutics, Inc. – NKTR
accessnewswire.com
NKTR
Pomerantz LLP Announces Class Action Filing Against Nektar Therapeutics, Inc. – NKTR
accessnewswire.com
NKTR
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
NKTR
NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
globenewswire.com
NKTR
Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit
businesswire.com
NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
accessnewswire.com
NKTR
Nektar Therapeutics to Participate in Two Investor Conferences in March
prnewswire.com
NKTR
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
prnewswire.com
ABBV
QTTB
HCWB
NKTR
LLY
INCY
PFE
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
prnewswire.com
NKTR
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
prnewswire.com
AMGN
CNTB
NKTR
APGE
LLY
OGN
ABBV
PFE
REGN
INCY